Monoclonal antibodies directed to cd52

Abstract

The invention provides antibody to canine or feline or equine antigens, e.g., canine CD52, and methods of making and using antibodies as described.

1 .- 23 . (canceled) 
     
     
         24 . A method of treating canine or feline lymphoma comprising administering a therapeutically effective amount of an antibody or antibody fragments which binds to CD52. 
     
     
         25 . The method of  claim 24 , wherein the antibody or antibody fragment recognizes a canine or feline CD52, and comprising a variable domain, wherein the variable domain comprises six CDR regions wherein the CDR regions are independently selected from the CDRs in a sequence selected from SEQ ID NOS: 5-8, wherein the CDR regions are as defined by Kabat, and wherein the antibody or antibody fragment comprises a light chain and a heavy chain and wherein the antibody or antibody fragment further comprises a constant domain which comprises sequences of canine or feline origin. 
     
     
         26 . The method of  claim 25 , wherein said variable domain comprises a variable domain from a sequence selected from SEQ ID NOS: 5-8. 
     
     
         27 . A method of treating a disease or condition in a canine or feline characterized by the presence of abnormal cells expressing CD52, wherein the method comprises administering a therapeutically effective amount of an antibody which binds to CD52. 
     
     
         28 . The method of  claim 27 , wherein the antibody or antibody fragment recognizes a canine or feline CD52, and comprising a variable domain, wherein the variable domain comprises six CDR regions wherein the CDR regions are independently selected from the CDRs in a sequence selected from SEQ ID NOS: 5-8, wherein the CDR regions are as defined by Kabat, and wherein the antibody or antibody fragment comprises a light chain and a heavy chain and wherein the antibody or antibody fragment further comprises a constant domain which comprises sequences of canine or feline origin. 
     
     
         29 . The method of  claim 28 , wherein antibody or antibody fragment canine or feline CD52, wherein said variable domain comprises a variable domain from a sequence selected from SEQ ID NOS: 5-8. 
     
     
         30 . The method of  claim 28 , wherein the disease or condition is selected from the group consisting of: acute inflammation, rheumatoid arthritis, transplant rejection, asthma, allergic inflammation, restenosis, arterial restenosis, inflammatory bowel disease, uveitis, multiple sclerosis, psoriasis, wound healing, lupus erythematosus, allergic rhinitis, atopic dermatitis, food allergies, diabetes mellitus, dermatitis, thrombotic thrombocytopenic purpura, encephalitis, leukocyte adhesion deficiency, rheumatic fever, psoriatic arthritis, osteoarthritis, ocular inflammatory disorders, progressive systemic sclerosis, primary biliary cirrhosis, CNS inflammatory disorder, antigen-antibody complex mediated diseases, autoimmune hemolytic anemia, ischemic heart disease, atherosclerosis, post-dialysis syndrome, leukemia, acquired immune deficiency syndrome, septic shock, lipid histiocytosis, and cancer. 
     
     
         31 . The method of  claim 28  further comprising administration of chemotherapy. 
     
     
         32 . The method of  claim 31 , wherein the chemotherapy comprises administration of one or more agents selected from cyclophosphamide, doxorubicin, vincristine, prednisone, L-asparaginase, cytoxan and adriamycin. 
     
     
         33 . The method of  claim 31 , wherein the chemotherapy spares or enhances effector cells. 
     
     
         34 . The method of  claim 31 , wherein the chemotherapy enhances or reduces interference with ADCC effects of antibody on cancer cells. 
     
     
         35 . The method of  claim 28 , wherein the method further comprises administration of a corticosteroid. 
     
     
         36 . The method of  claim 35 , wherein the corticosteroid is prednisone. 
     
     
         37 . The method of  claim 28 , wherein the method further comprises the administration of radiation. 
     
     
         38 . The method of  claim 28 , wherein the method comprises co-administration of antibody to CD20 and CD52. 
     
     
         39 . The method of  claim 28 , wherein the method comprises administering the antibody or antibody fragment to treat or inhibit recurrence of cancer following treatment with radiation or chemotherapy. 
     
     
         40 . A method of diagnosing a disease or condition treatable with an antibody or antibody fragment which recognizes CD52, wherein the method comprises obtaining a tissue sample and measuring the binding of said antibody or antibody fragment. 
     
     
         41 . The method of  claim 41 , wherein the antibody or antibody fragment recognizes a canine or feline CD52, and comprising a variable domain, wherein the variable domain comprises six CDR regions wherein the CDR regions are independently selected from the CDRs in a sequence selected from SEQ ID NOS: 5-8, wherein the CDR regions are as defined by Kabat, and wherein the antibody or antibody fragment comprises a light chain and a heavy chain and wherein the antibody or antibody fragment further comprises a constant domain which comprises sequences of canine or feline origin. 
     
     
         42 . The method of  claim 24 , wherein the antibody or antibody fragment which binds to CD52 results in leukocyte depletion from between 36%-95% of a pre-dosing level.